JPMorgan Chase & Co. upgraded shares of TransMedics Group (NASDAQ:TMDX – Get Rating) from a neutral rating to an overweight rating in a report published on Tuesday, Marketbeat reports. JPMorgan Chase & Co. currently has $48.00 price target on the stock.
Several other research analysts have also recently weighed in on TMDX. Cowen lifted their price target on TransMedics Group from $39.00 to $45.00 and gave the company a maintains rating in a research report on Tuesday, July 26th. Cowen boosted their price objective on TransMedics Group from $39.00 to $45.00 and gave the company an outperform rating in a research report on Tuesday, July 26th. Morgan Stanley boosted their price target on TransMedics Group from $25.00 to $34.00 and gave the stock an equal weight rating in a research report on Wednesday, June 29th. Finally, Canaccord Genuity Group boosted their price target on TransMedics Group from $39.00 to $46.00 in a research report on Wednesday, May 4th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of Moderate Buy and an average price target of $43.86.
TransMedics Group Stock Performance
Shares of TransMedics Group stock opened at $37.28 on Tuesday. The firm has a market cap of $1.04 billion, a P/E ratio of -21.93 and a beta of 1.63. The company has a current ratio of 5.22, a quick ratio of 4.40 and a debt-to-equity ratio of 0.59. TransMedics Group has a 12 month low of $10.00 and a 12 month high of $42.00. The stock’s fifty day moving average price is $31.48 and its 200-day moving average price is $24.63.
In other news, VP John F. Carey sold 3,320 shares of the stock in a transaction dated Monday, June 27th. The stock was sold at an average price of $32.59, for a total value of $108,198.80. Following the transaction, the vice president now owns 379 shares in the company, valued at approximately $12,351.61. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, VP John F. Carey sold 3,320 shares of the company’s stock in a transaction dated Monday, June 27th. The stock was sold at an average price of $32.59, for a total value of $108,198.80. Following the completion of the sale, the vice president now directly owns 379 shares of the company’s stock, valued at approximately $12,351.61. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Tamer I. Khayal sold 13,504 shares of the company’s stock in a transaction dated Friday, July 29th. The shares were sold at an average price of $40.01, for a total value of $540,295.04. Following the completion of the sale, the insider now directly owns 46,076 shares of the company’s stock, valued at $1,843,500.76. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 151,814 shares of company stock worth $5,633,336. 8.70% of the stock is currently owned by insiders.
Institutional Trading of TransMedics Group
A number of hedge funds have recently added to or reduced their stakes in TMDX. FNY Investment Advisers LLC acquired a new stake in TransMedics Group during the 2nd quarter worth approximately $31,000. Ensign Peak Advisors Inc acquired a new stake in TransMedics Group during the 4th quarter worth approximately $97,000. Allspring Global Investments Holdings LLC acquired a new stake in shares of TransMedics Group in the 4th quarter valued at approximately $99,000. Amalgamated Bank acquired a new stake in shares of TransMedics Group in the 1st quarter valued at approximately $114,000. Finally, Captrust Financial Advisors lifted its holdings in shares of TransMedics Group by 738.8% in the 1st quarter. Captrust Financial Advisors now owns 5,788 shares of the company’s stock valued at $156,000 after buying an additional 5,098 shares during the period. 71.75% of the stock is owned by institutional investors and hedge funds.
About TransMedics Group
TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
- Get a free copy of the StockNews.com research report on TransMedics Group (TMDX)
- AMD Q2 Earnings Beat Expectations Significantly, Is AMD A Buy?
- 3 Health Care Stocks in Great Financial Health
- Amazon Names Itself A Top Stock Of Q3 Contender
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Market Fundamentals Drive Results For The Williams Companies
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.